Dementia-related neuropsychiatric symptoms: inequalities in pharmacological treatment and institutionalization.

antidepressant drugs antipsychotic drugs dementia deprivation index inequalities neuropsychiatric symptoms nursing home prevalence

Journal

Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304

Informations de publication

Date de publication:
2019
Historique:
received: 17 03 2019
accepted: 24 06 2019
entrez: 16 8 2019
pubmed: 16 8 2019
medline: 16 8 2019
Statut: epublish

Résumé

Dementia-related neuropsychiatric symptoms (NPS) are the main determinant of family stress and institutionalization of patients. This study aimed to identify inequalities by gender and socioeconomic status in the management of NPS in patients diagnosed with dementia. An observational study was carried out to study all the cases of dementia in the corporate database of the Basque Health Service (29,864 patients). The prescription of antipsychotics and antidepressants and admission to a nursing home were used to establish the presence of NPS. The socioeconomic status of individuals was classified by a deprivation index. Logistic regressions were used to identify drivers for drug prescriptions and institutionalization. NPS are poorly recorded in the clinical databases (12%). Neuropsychiatric symptoms were severe enough in two thirds of patients with dementia to be treated with psychoactive medication. Institutionalization showed an increase from those who did not receive medication to those who had been prescribed antidepressants (OR: 1.546), antipsychotics (OR: 2.075) or both (OR: 2.741). The resulting inequalities were the increased prescription of antidepressant drugs in women and more nursing-home admissions for women who were the least socioeconomically deprived and men who were the most deprived. In large clinical databases, psychoactive drugs prescriptions can be useful to underscore the considerable burden of dementia-related NPS. Specific tools are needed to monitor social and health care programs targeted to dementia-related NPS from a population perspective. Programs aimed at reducing the family burden of care of dementia patients at home become the key elements in reducing inequalities in these patients' care. Socioeconomic status is the most important driver of inequality, and gender inequality may simply be hidden within the social environment. Integrated programs boosting the continuity of care are an objective for which compliance could be measured according to the NPS coding in the electronic health record.

Sections du résumé

BACKGROUND BACKGROUND
Dementia-related neuropsychiatric symptoms (NPS) are the main determinant of family stress and institutionalization of patients. This study aimed to identify inequalities by gender and socioeconomic status in the management of NPS in patients diagnosed with dementia.
METHODS METHODS
An observational study was carried out to study all the cases of dementia in the corporate database of the Basque Health Service (29,864 patients). The prescription of antipsychotics and antidepressants and admission to a nursing home were used to establish the presence of NPS. The socioeconomic status of individuals was classified by a deprivation index. Logistic regressions were used to identify drivers for drug prescriptions and institutionalization.
RESULTS RESULTS
NPS are poorly recorded in the clinical databases (12%). Neuropsychiatric symptoms were severe enough in two thirds of patients with dementia to be treated with psychoactive medication. Institutionalization showed an increase from those who did not receive medication to those who had been prescribed antidepressants (OR: 1.546), antipsychotics (OR: 2.075) or both (OR: 2.741). The resulting inequalities were the increased prescription of antidepressant drugs in women and more nursing-home admissions for women who were the least socioeconomically deprived and men who were the most deprived.
CONCLUSIONS CONCLUSIONS
In large clinical databases, psychoactive drugs prescriptions can be useful to underscore the considerable burden of dementia-related NPS. Specific tools are needed to monitor social and health care programs targeted to dementia-related NPS from a population perspective. Programs aimed at reducing the family burden of care of dementia patients at home become the key elements in reducing inequalities in these patients' care. Socioeconomic status is the most important driver of inequality, and gender inequality may simply be hidden within the social environment. Integrated programs boosting the continuity of care are an objective for which compliance could be measured according to the NPS coding in the electronic health record.

Identifiants

pubmed: 31413574
doi: 10.2147/NDT.S209008
pii: 209008
pmc: PMC6657654
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2027-2034

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare in this work.

Références

Neurologia (Engl Ed). 2021 Jul-Aug;36(6):418-425
pubmed: 34238524
Gac Sanit. 2008 May-Jun;22(3):179-87
pubmed: 18579042
Int Psychogeriatr. 2007 Jun;19(3):345-54
pubmed: 17386120
Eur J Ageing. 2010 Jun;7(2):101-109
pubmed: 20730084
Dementia (London). 2019 Oct-Nov;18(7-8):2925-2949
pubmed: 29557183
Alzheimer Dis Assoc Disord. 2004 Apr-Jun;18(2):83-9
pubmed: 15249852
Drug Saf. 2009;32(11):1075-87
pubmed: 19810779
Drug Saf. 2017 Aug;40(8):647-649
pubmed: 28660499
BMC Geriatr. 2016 May 18;16:106
pubmed: 27193287
Lancet Public Health. 2017 Mar;2(3):e149-e156
pubmed: 29253388
J Alzheimers Dis. 2015;43(4):1293-302
pubmed: 25159671
Front Neurol. 2012 May 07;3:73
pubmed: 22586419
Gac Sanit. 2011 Dec;25 Suppl 2:108-14
pubmed: 22079333
JAMA Psychiatry. 2018 Jul 1;75(7):723-732
pubmed: 29799983
J Clin Psychiatry. 1987 May;48 Suppl:9-15
pubmed: 3553166
J Affect Disord. 2016 Jan 15;190:264-271
pubmed: 26540080
J Alzheimers Dis. 2018;62(1):99-113
pubmed: 29439334
Lancet. 2017 Mar 25;389(10075):1229-1237
pubmed: 28159391
Lancet. 2011 Mar 19;377(9770):1019-31
pubmed: 21371747
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
Am J Alzheimers Dis Other Demen. 2018 Nov;33(7):450-457
pubmed: 29969907
J Clin Psychiatry. 2015 Oct;76(10):1346-53
pubmed: 26528641
Fam Process. 2018 Sep;57(3):694-706
pubmed: 29034464
J Alzheimers Dis. 2016 Aug 10;54(1):337-49
pubmed: 27567819
Lancet. 2005 Dec 17;366(9503):2112-7
pubmed: 16360788
Gac Sanit. 2014 Sep-Oct;28(5):389-92
pubmed: 24889701
Drug Saf. 2017 Aug;40(8):679-692
pubmed: 28439716

Auteurs

Javier Mar (J)

Clinical Management Unit, OSI Alto Deba, Arrasate-Mondragón, España.
AP-OSIs Gipuzkoa Research Unit, OSI Alto Deba, Arrasate-Mondragón, España.
Economic Evaluation Department, Health Services Research on Chronic Patients Network (REDISSEC), Bilbao, Spain.
Economic Evaluation Department, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain.

Arantzazu Arrospide (A)

AP-OSIs Gipuzkoa Research Unit, OSI Alto Deba, Arrasate-Mondragón, España.
Economic Evaluation Department, Health Services Research on Chronic Patients Network (REDISSEC), Bilbao, Spain.
Economic Evaluation Department, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain.

Myriam Soto-Gordoa (M)

Departamento de Ingeniería de Organización, Mondragón Unibertsitatea, Arrasate-Mondragón, España.

Álvaro Iruin (Á)

Economic Evaluation Department, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain.
Psychiatry Service, Gipuzkoa Mental Health Network, Donostia-San Sebastián, España.

Mikel Tainta (M)

Psychiatry Service, CITA Alzheimer Foundation, Donostia-San Sebastián, España.
Neurology Service, OSI Goierri-Alto Urola, Zumárraga, España.

Andrea Gabilondo (A)

Economic Evaluation Department, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain.
Psychiatry Service, Gipuzkoa Mental Health Network, Donostia-San Sebastián, España.

Lore Mar-Barrutia (L)

Psychiatry Service, Hospital Bellvitge, Hospitalet de Llobregat, España.

Montserrat Calvo (M)

Health Department, Basque Government, Vitoria-Gasteiz, España.

Maider Mateos (M)

Health Department, Basque Government, Vitoria-Gasteiz, España.

Oliver Ibarrondo (O)

AP-OSIs Gipuzkoa Research Unit, OSI Alto Deba, Arrasate-Mondragón, España.
Economic Evaluation Department, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain.

Classifications MeSH